

Skeletal Muscle Relaxants Effective 06/25/2018 ☐ MassHealth UPPL Plan ☐ Prior Authorization □ Commercial/Exchange **Program Type** ☐ Quantity Limit □ Pharmacy Benefit **Benefit** ☐ Medical Benefit Specialty N/A Limitations **Medical and Specialty Medications** Phone: 877-519-1908 All Plans Fax: 855-540-3693 Contact Information **Non-Specialty Medications** All Plans Phone: 800-711-4555 Fax: 844-403-1029

Overview

Exceptions

Prescriptions that meet the initial step therapy requirements will adjudicate automatically at the point of sale. If the prescription does not meet the initial step therapy requirements, the prescription will deny with a message indicating that prior authorization (PA) is required. Refer to the criteria below and submit a PA request for the members who do not meet the initial step therapy requirements at the point of sale.

Initial Step-Therapy Requirements:

N/A

First-Line: Medications listed on first-line are covered without prior-authorization.

Second-Line: Second-line medications will pay if the member has filled at least three different first-line medications or a second-line medication within the past 180 days.

Coverage Guidelines

If a member does not meet the initial step therapy requirements, then approval of a second-line medication will be granted if the member has had a documented inadequate response, side effect, or allergy to at least three (3) different preferred generic skeletal muscle relaxants.

FIRST-LINE	SECOND-LINE
Generic skeletal muscle relaxants including:	carisoprodol/ASA (Soma Compound)
chlorzoxazone	carisoprodol/ASA/codeine (Soma
cyclobenzaprine (Flexeril)	Compound/codeine)
methocarbamol (Robaxin)	metaxalone (Skelaxin [®])
orphenadrine citrate ER	
orphenadrine/ASA/Caffeine	
baclofen (Lioresal)	
dantrolene (Dantrium)	
tizanidine (Zanaflex)	
carisoprodol 350mg tablets (Soma)	

^{*} Please note: carisoprodol (Soma®) 250mg tablets, Lorzone® tablets, and Amrix® capsules are a plan exclusion

Limitations

1. Approvals will be granted for 12 months.

References

N/A

Review History

09/01/06 – Implemented

06/26/06 - Reviewed

06/18/07 - Reviewed

06/16/08 - Reviewed

06/15/09 – Updated

06/21/10 - Reviewed

06/27/11 - Reviewed

12/1/11 – Lorzone plan exclusion (11/21/11 drug file)

06/25/12 - Reviewed

06/24/13 - 4 trials

06/23/14 - Reviewed

06/22/15 - Reviewed

6/27/16 - Added carisoprodol to 1st step

06/26/17 - Reviewed

06/25/18 – Removed brand, added generic.

